Vortioxetine Hydrobromide

中国人何时才能理解抑郁症？每当股市大跌，股吧评论区最常见的回复是什么？ "跌得我都要抑郁了。" 你一边开着这个玩笑，一边对着刚暴跌的账户猛按卖出。你对"抑郁"的理解，比上市公司财报里的数字水分还大。 这就是中国人理解抑郁症最真实的写照——不是不懂，是不想懂；不是看不见，是选择性失明。一、先看数据：9500万，这个数字比A股所有散户加起来还多 先上硬货。 据国家疾控中心2025年数据显示，我国各类精神障碍终生患病率达16.6%，其中抑郁症患者超9500万人，相当于每14-15人中就有1人患病。而在1990-2021年这三十余年间，患病人数增幅高达54%。全球抑郁症患者约3.32亿人，WHO预测到2030年抑郁症将成为仅次于冠心病的全球第二大疾病负担。 9500万！你知道这意味着什么吗？相当于A股所有散户加起来还多一个广东省的人口。这些人就坐在你身边——写字楼隔板对面的同事，地铁里面无表情的陌生人，甚至在深夜天台独自发呆的自己。 但更扎心的不是数字有多大，而是中国人对它的态度。你能想象吗？中国抑郁症就诊率仅为9.5%，规范治疗率更是低至0.5%。什么意思？9500万患者里，超过8500万人在硬扛！ 好比你买了一只股票，股价已经跌到0.5元了，你既不卖出也不补仓，就眼睁睁看着它挂在那里。你能这样炒股，但你为什么要让你的身体和大脑这样炒股？二、病耻感：中国人最昂贵的隐形税 为什么8500万人不去看病？ 因为在中国，承认自己抑郁，比承认自己买在高点被套还丢人。 精神卫生调查显示，在中国社会，受"家丑不可外扬"观念影响，心理问题的家庭污名化现象极为严重。患者家人习惯把痛苦藏于门后，怕被议论、被贴上"不正常"的标签。有人去精神科看病，被街坊邻居议论了三天；有人因为"情绪不好"被领导建议"想开点就行"——抑郁症，不是想开点就开得了的。 甚至有政协委员指出，部分公职人员存在"先入为主地认为精神障碍患者必然具有高风险行为"的偏见，存在对精神障碍患者的污名化和歧视等严重问题。 好比你病得咳血了，老板指着你鼻子说："你就是太懒！多加班就好了！" 抑郁症的经济杀伤力远比任何经济危机都大。根据医学期刊《柳叶刀》的报告，抑郁症导致的缺勤和工作效率低下，每年给全球经济造成超过1万亿美元的损失。你公司里最上进的同事突然辞职了，不是因为找到了更好的offer，而是他的大脑实在太累了，连起床都需要巨大的勇气。 在A股，我们有生物医药板块，有AI人工智能概念股，有几万亿的家电消费龙头——唯独没有"情绪健康"这个赛道的一席之地。不是这个赛道没有价值，而是这个赛道还在冰山下面，等着被政策、需求和资本的合力砸开。三、市场有多大？抗抑郁药97亿，只是冰山浮出水面的那一点 你以为市场不大？那你是没见过真正的金矿。 根据东北证券2026年5月最新发布的CNS行业深度报告：国内主流抗抑郁药市场规模已达97.29亿元，2016-2025年复合增长率为8.1%。注意，这还只是"主流抗抑郁药"，还不包括线上心理健康平台、数字疗法、心理咨询、精神专科医疗服务等整个产业链的完整蛋糕。 全球数字心理健康市场规模在2025年已达到275.5亿美元，预计2026年增长至320.6亿美元，复合年增长率16.4%。而全球心理健康平台市场（包括线上咨询、AI辅助诊断、情绪管理等）2025年已达48.6亿美元，2026年预计56.1亿美元，年增速15.5%。 而中国呢？当前线上精神心理诊疗市场规模预计2026年突破80亿元，年增速超35%。随着国家政策全面推动"社会心理服务体系"建设，这个市场正在从"地下"走向"阳光"。 就诊率9.5%、规范治疗率0.5%——这两个数据意味着什么？意味着一旦社会认知障碍被打破、医保支付机制进一步完善，市场空间可能有10倍、20倍的爆发增长。四、政策来了：25个部门联手，再不上车就晚了 2026年3月，国家卫健委、中宣部、中央政法委、教育部等25个部门联合印发《健全社会心理服务体系和危机干预机制实施方案》，这个规格，比当年搞房地产去库存还高。 关键目标是什么？到2030年，实现"覆盖全人群、全生命周期的社会心理服务体系和危机干预机制"。包括：各级公立精神专科医院必须设心理门诊；每个县(区)至少有1所医院提供心理门诊服务；80%以上的村和社区设置心理咨询室；各省建成省级12356心理援助平台。 此外，在医疗服务价格动态调整中统筹关注心理治疗、心理咨询等项目价格，合理确定价格水平，更好体现技术劳务价值。这意味着心理治疗的价格可能会迎来长期性的涨价通道。 这就像一个政府开出的天量采购订单，只是订单的锚点不是你熟悉的芯片或空调，而是"心理"。25个部门同时在推这个事情，你如果还看不见，那我就一个字：服。五、企业布局：谁在收割这个"最沉默的金矿"？ 先看创新药。 绿叶制药：自主研发的1类创新药若欣林（托鲁地文拉法辛），是国内首个SNDRI类抗抑郁新药，填补了该领域空白，已通过谈判进入国家医保目录，目前正处快速放量期。 恩华药业：作为国内唯一专注CNS（中枢神经系统）领域的上市企业，全梯队管线已陆续出清集采风险。NH102（对标度洛西汀）和R-氯胺酮双剂型同步推进，正在快速起跑。 吉贝尔：抗抑郁一类新药JJH201501已完成III期临床试验，研究结果显示疗效显著优于安慰剂组，与氢溴酸伏硫西汀片（同类药品中国境内年销售额约5.84亿元）疗效相当，且安全性和耐受性良好。一旦获批，数十亿的增量可期。 康弘药业等正针对快速起效的R-氯胺酮、NAS等前沿靶点进行差异化开发。 再看线上心理健康平台。国内"好心情"、"简单心理"、"壹心理"等平台提供视频问诊、AI情绪日记、团体辅导服务。政策允许首诊后复诊可线上进行，市场正以年增长35%以上的速度狂飙。AI辅助诊断技术也在快速渗透，通过语音语调、面部表情、文本分析筛查抑郁症和双相障碍，准确率已超过85%。相关上市公司虽然还未形成独立板块，但迟早会以"数字医疗"或"AI+医疗"的形态浮出水面。 而你知道最有意思的是什么吗？AI和数字疗法正在给中国精神医疗带来革命式的突破。比如AI监测高校学生社交平台异常言论来主动干预高危个体；NMPA已认证了多款数字疗法APP如正念训练、CBT交互程序等。这类数字疗法不仅边际成本极低，而且一旦覆盖到3000万、5000万用户量，其估值逻辑将是互联网平台的生态估值，而不是传统药的PE估值。六、风险：理性投资者必须思考的三个坑 我不会只给甜枣，不给巴掌。投资"抑郁赛道"必须想清楚三个问题： 第一，慢病治疗周期太长，医保支付覆盖率仍然不足。精神治疗不像感冒药，吃三天就好。患者平均治疗周期长达半年至一年，心理咨询目前多为自费，长程治疗经济负担重。虽然政策在推动医保覆盖，但进程远未完成。 第二，市场教育成本极高。在9500万患者中，就诊率仅9.5%。这意味着要普及抑郁症的科学认知、消除病耻感，企业先要做的是免费的心理科普教育，这可不是一天两天能砸出来的。 第三，业绩兑现周期长。创新药动辄十年研发周期；而线上医疗平台还处在"烧钱换流量"的阶段，距离盈利还早。七、结语：8000万沉默的"用户"，正在等待一个被倾听的"产品经理" 2026年的中国，9500万抑郁症患者，就诊率不足10%，规范治疗率不足1%。 这意味着什么？意味着这个庞大的市场，几乎还是一张白纸。它不缺少患者——9500万是最保守的统计口径；不缺少政策——25个部门联合发文推动；不缺少支付端——心理治疗正逐步纳入医保，AI和数字疗法正在把单次成本大幅压低。 它缺的，是一个能够打破沉默、把"抑郁"从"情绪问题"重定义为"可管理、可治愈、可商业化的疾病"的社会共识。 从投资角度看，当前A股和精神心理健康相关的上市公司：绿叶制药、恩华药业、吉贝尔、康弘药业等，正处于创新药放量或III期临床结果公布的窗口期；而线上精神健康平台、AI心理诊断、数字疗法等新赛道，还处于"没被机构盯上"的早期卡位阶段，未来3-5年将迎来爆发性成长机会。 8000多万仍在孤独中沉默的中国人，需要一个值得他们信赖、可靠且真正可及的解决方案。而这个机会，也值得每一个投资者，在那些尚未有人关注的角落里，投入自己的时间和资本。 A股不缺概念，缺的是在正确的时间、正确的位置，买到真正有价值的东西。而抑郁症这个赛道，正在从黑暗中，慢慢被点亮。 你上不上车，是时间的问题，不是你犹豫的问题。 以上仅为个人投资思考，不构成投资建议。股市有风险，投资需谨慎，我看对了就说，看错了也认，请大家对自己钱包负责。

NEW YORK, NY / ACCESS Newswire / May 19, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing novel peptide-based therapies for stress-related neuropsychiatric disorders, today announced two strategic engagements to support the advancement of its lead candidate, PT00114. The Company has engaged Floyd Regulatory Strategic Consulting, led by regulatory affairs veteran Dr. Eric Floyd, Ph.D., MBA, as Regulatory Affairs Advisor, and DanforthHealth, a premier life science operational consulting firm, to establish institutional-grade operational processes and infrastructure. Together, these engagements reflect Protagenic's deliberate, lean operating model concentrating resources and expertise on PT00114's Phase 2 advancement while positioning the Company for long-term value creation for patients and shareholders. Dr. Floyd brings more than 25 years of senior regulatory leadership experience in the pharmaceutical and biopharmaceutical industries. As U.S. Head of Regulatory Affairs at Lundbeck, he led strategic regulatory activities supporting the U.S. approvals of Abilify Maintena ® (aripiprazole extended-release injectable suspension), Trintellix ® (vortioxetine), and Rexulti ® (brexpiprazole) - three landmark CNS products spanning schizophrenia and major depressive disorder. Dr. Floyd has also held senior regulatory roles at Novartis, Cephalon, and Axovant Sciences, and most recently served as Global Head of Regulatory Affairs at Neurogene, Inc. He serves as adjunct faculty in Neuroscience at Harvard Medical School and Wake Forest University School of Medicine. As Regulatory Affairs Advisor, Dr. Floyd will lead Protagenic's regulatory strategy for PT00114, including IND maintenance, pre-Phase 2 FDA meeting preparation and Phase 2 submission planning. "Eric's regulatory track record in CNS and his leadership on three of the most important CNS approvals of the past decade is exceptional," said Bill Nichols Jr., President of Protagenic Therapeutics . "And his deep knowledge of FDA's expectations in neuropsychiatric drug development is precisely what PT00114 requires as we advance toward Phase 2." "PT00114's mechanism of action targeting the TCAP pathway, and the clean Phase 1 safety data the program has generated, create a strong foundation for a rigorous Phase 2 program," said Dr. Eric Floyd, Ph.D., MBA, Founder and Principal of Floyd Regulatory Strategic Consulting . "I have spent my career moving CNS therapies from concept to patients and I look forward to bringing that experience to bear for Protagenic at this pivotal moment." Protagenic has also engaged the finance & human resources consulting arm of Danforth Health to establish streamlined operational processes and infrastructure aligned with the Company's current stage and strategic priorities. Danforth has served more than 1,800 life science companies across business operations, development, and commercialization, and brings a flexible, scalable team of cross-functional biotech professionals. Danforth's extensive strategic relationships across the life science ecosystem - spanning investors, clinical service providers, and investment banks - provide Protagenic with access to a network very well uniquely suited to accelerate its development trajectory. "Danforth has built an unmatched capability serving exactly the kind of company Protagenic is today," said Mr. Nichols. "Their flexible, scalable model allows us to build institutional-grade operations - investor-ready financial processes, disciplined governance, and strategic access to the broader life science ecosystem - without the overhead of a large internal infrastructure. That is precisely the model Protagenic needs as we advance PT00114 toward Phase 2." These engagements build on recent operational and clinical milestones at Protagenic, including the completion of the Phytanix separation in March 2026, which strengthened the Company's balance sheet by removing more than $6.3 million in liabilities and more than $1 million in annualized costs. Coupled with its completed PT00114 Phase 1 multiple-dose safety and tolerability study, these milestones position Protagenic to advance PT00114 into Phase 2 enrollment in 2026 with a focused team, clean capital structure and experienced advisory partners. About PT00114 PT00114 is Protagenic's lead clinical asset - a first-in-class investigational neuropeptide targeting the TCAP pathway for the treatment of stress-related neuropsychiatric disorders, including anxiety, PTSD, and treatment-resistant depression. In December 2025, the program reported positive Phase 1 multiple-dose safety and tolerability data, with no serious adverse events observed across dose levels. Protagenic plans to advance PT00114 into Phase 2 clinical studies in 2026. About Protagenic Therapeutics, Inc. Protagenic Therapeutics, Inc. (OTCQB: PTIX) is a clinical-stage biopharmaceutical company dedicated to developing breakthrough peptide-based treatments for stress-related neuropsychiatric disorders. The Company is headquartered in New York, NY. About Floyd Regulatory Strategic Consulting Floyd Regulatory Strategic Consulting is a specialized regulatory affairs advisory firm founded and led by Dr. Eric Floyd, Ph.D., MBA. With more than 25 years of experience in pharmaceutical and biopharmaceutical regulatory affairs, Dr. Floyd provides strategic regulatory guidance to clinical-stage companies across CNS, oncology, and rare disease therapeutic areas. The firm's expertise spans IND strategy, FDA engagement and meeting management, clinical protocol regulatory review, NDA/BLA planning, and submission management. About Danforth Health Danforth Health is a unified platform purpose-built to empower life science innovation. By integrating the capabilities of best-in-class affiliates, Danforth Health provides tailored, cross-functional support across finance and human resources, investor and public relations, discovery and development, regulatory and clinical, commercial and marketing, market research and analytics, and market access and value. The model is built for flexibility, scalability, and impact - serving life science companies at any stage and helping them move faster, smarter, and more efficiently to achieve transformative outcomes for patients. Headquartered in Waltham, Massachusetts, Danforth Health has partnered with more than 1,800 life science companies around the world. Learn more at . Trademark Notice Abilify Maintena ® is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Trintellix ® is a registered trademark of H. Lundbeck A/S. Rexulti ® is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Danforth Advisors ™ is a trademark of Danforth Advisors, LLC. All other trademarks are the property of their respective owners. For more information, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including but not limited to statements regarding the anticipated role and contribution of Dr. Floyd, the planned timing of Phase 2 enrollment for PT00114, and the therapeutic potential of PT00114. These statements are based on current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Protagenic Therapeutics undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Investor & Media Contact: Protagenic Therapeutics, Inc. | info@protagenic.com | SOURCE: Protagenic Therapeutics, Inc. View the original press release on ACCESS Newswire